Statistical analyses
EVENT
The study was planned to recruit up to 20 patients, 15 in the dose finding cohort and five as a dose expansion. A pragmatic sample of 15 patients would yield a 95% confidence interval between 4 and 48% for an actual grade 3–4 event rate of 20% which was considered suitable precision for a phase 1 pilot study. Time to progression was calculated from the first day of treatment to progression using the Kaplan–Meier method. Flow cytometry and gene expression data were analysed using GraphPad Prism (version 6.0; GraphPad Software, San Diego, CA). Data were analysed using Wilcoxon’s matched pairs signed rank test compared with baseline samples (*